How to buy Salarius Pharmaceuticals stock (SLRX)

Salarius Pharmaceuticals is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.55 – an increase of 5.45% over the previous week. Salarius Pharmaceuticals employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Salarius Pharmaceuticals stock

Buy Salarius Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Salarius Pharmaceuticals stock price (NASDAQ: SLRX)

Use our graph to track the performance of SLRX stocks over time.

Salarius Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.55
52-week range	$1.22 - $6.33
50-day moving average more info button	$1.53
200-day moving average more info button	$2.65
Wall St. target price	$26.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.14

Is it a good time to buy Salarius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Salarius Pharmaceuticals price performance over time

Historical closes compared with the close of $1.55 from 2024-12-20

1 week (2024-12-13)	5.45%
1 month (2024-11-22)	13.14%
3 months (2024-09-20)	-9.36%
6 months (2024-06-21)	-38.49%

1 year (2023-12-22)	159.63%
2 years (2022-12-22)	-83.58%
3 years (2021-12-22)	105.8
5 years (2019-12-20)	816

Salarius Pharmaceuticals financials

Gross profit TTM	$-15,836,828
Return on assets TTM	-53.99%
Return on equity TTM	-119.83%
Profit margin	0%
Book value	$10.74
Market Capitalization more info button	$1.8 million

TTM: trailing 12 months

Salarius Pharmaceuticals share dividends

We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.

Have Salarius Pharmaceuticals's shares ever split?

Salarius Pharmaceuticals's shares were split on a 1:8 basis on 16 June 2024 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.

Salarius Pharmaceuticals share price volatility

Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $1.22 up to $6.328. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 0.932. This would suggest that Salarius Pharmaceuticals's shares are less volatile than average (for this exchange).

Salarius Pharmaceuticals overview

Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Salarius Pharmaceuticals is owned by insiders or institutions?
Currently 2.517% of Salarius Pharmaceuticals shares are held by insiders and 0.364% by institutions. How many people work for Salarius Pharmaceuticals?
Latest data suggests 2 work at Salarius Pharmaceuticals. When does the fiscal year end for Salarius Pharmaceuticals?
Salarius Pharmaceuticals's fiscal year ends in December. Where is Salarius Pharmaceuticals based?
Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021 What is Salarius Pharmaceuticals's ISIN number?
Salarius Pharmaceuticals's international securities identification number is: US79400X1072 What is Salarius Pharmaceuticals's CUSIP number?
Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 79400X107